Cliniche Gavazzeni S.p.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Medical Oncology department at Cliniche Gavazzeni is conducting studies that address acute coronary syndrome and aim to lower the risk of repeat heart attacks, while separate trials evaluate new oral anticoagulants for patients with atrial fibrillation. Additional research explores therapies designed to cut major adverse cardiovascular events in individuals with a history of myocardial infarction.
- Acute coronary syndrome
- Atrial fibrillation
- Cardiovascular event prevention
- Obesity‑related cardiovascular risk
These investigations are part of the site’s broader effort to improve heart health outcomes for the Bergamo community and beyond.
Neoplasms
A robust portfolio of oncology trials at Cliniche Gavazzeni targets advanced solid tumors, with a focus on hormone‑responsive breast cancer, various forms of lung cancer, and rare lymphomas. The studies compare innovative antibody‑drug conjugates and cellular therapies against standard chemotherapy to extend survival and enhance response rates.
- Advanced solid tumors
- Hormone‑positive breast cancer
- Metastatic non‑small cell lung cancer
- Small cell lung cancer
- Mantle cell lymphoma
By testing novel agents, the site contributes to advancing cancer care across multiple disease subtypes.
Nutritional and Metabolic Diseases
The clinic’s metabolic research includes a trial of a peptide‑based therapy aimed at improving cardiovascular safety in patients with obesity. Participants receive the investigational drug to assess its impact on weight reduction and related metabolic parameters, with the goal of lowering heart‑related complications.
- Obesity management
- Metabolic syndrome
- Weight‑related cardiovascular outcomes
These efforts align with broader public‑health strategies to combat the growing burden of metabolic disease in Italy.
Environment and Public Health
Beyond individual disease trials, Cliniche Gavazzeni engages in research that examines how environmental exposures influence cancer incidence and cardiovascular risk. Studies also evaluate community‑based screening programs and health‑care delivery models to improve early detection and treatment accessibility.
- Environmental risk factors for cancer
- Public health screening initiatives
- Health‑care delivery research
This multidisciplinary approach supports the institution’s commitment to population health and preventive medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 5 therapeutic areas and 15 of 112 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 106 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1AstraZeneca AB3active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cliniche Gavazzeni S.p.A.
lock Showing 1 of 53 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 112 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 10 | Unknown | 2024-04-26 | 2025-11-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.